All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On the 7th of November 2019, TAC01-CD19 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after at least 2 prior systemic therapies.1
TAC01-CD19 is a T cell antigen coupler (TAC) that is distinct from chimeric antigen receptor T cells (CAR-T). This TAC receptor product employs patient-derived genetically engineered T cells to target CD19, a B-cell marker expressed on the surface of B-cell tumors, independent of the Major Histocompatibility Complex.2 Preclinical data indicate that TAC01-CD19 could be highly efficacious without treatment-associated toxicity in animal models of CD19-positive B-cell malignancies.3
A phase I/II study (TACTIC-19) NCT03880279 evaluating the efficacy and safety of TAC01-CD19 in patients with CD19-positive B-cell malignancies including DLBCL is anticipated to start by the end of 2019.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox